ARNOLD L ORONSKY
CIK 1207833 · last filed 2020-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.35M
Companies
12
Total Filings
55
Lifetime Open-Market Net
-$575.83M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PMVP | Director | 6,469,911 | $1.24 | $8.02M | $1.99M | 2 | 2020-10-02 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 388,766 | $27.00 | $10.50M | $1.00M | 6 | 2020-10-02 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 37,506 | $15.50 | $581.3K | $600.0K | 18 | 2020-05-29 |
| Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | 10%+ Owner | 45,411 | $1.73 | $78.3K | -$17.17M | 1 | 2018-10-22 |
| TESARO, Inc. (TSRO) Delisted | Director | 3,817 | — | — | $10.73M | 10 | 2018-08-09 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | 1,404,515 | $0.39 | $552.8K | $0 | 4 | 2017-04-26 |
| MGNX | Director | 1,708,716 | $3.70 | $6.32M | -$7.30M | 3 | 2014-02-18 |
| Marketo, Inc. (MKTO) Delisted | 10%+ Owner | 7,663,756 | — | — | -$637.37M | 1 | 2013-09-18 |
| Trius Therapeutics Inc (TSRX) Delisted | 3,548,643 | — | — | $61.37M | 1 | 2010-08-10 | |
| MBRX | Director | 1,536 | $2.12 | $3.3K | $2.32M | 4 | 2009-06-24 |
| ANESIVA, INC. (ANSV) Delisted | Director | 132,388 | — | — | $8.00M | 3 | 2008-05-12 |
| ReShape Weightloss Inc. (ETRM) Delisted | 10%+ Owner | 257,794 | — | — | $0 | 1 | 2007-11-21 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-01 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-05 | TESARO, Inc. (TSRO) Delisted | Grant (A) | +335 | $0 | EDGAR |
| 2017-06-02 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-26 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Exer (X) | +3,688 | $0 | EDGAR |
| 2017-03-27 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-03-02 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-03 | TESARO, Inc. (TSRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-31 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-18 | TESARO, Inc. (TSRO) Delisted | Buy (P) | +142,085 | $5.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.